Valeant (VRX) Enters Amended Credit Agreement; Extends Date of 10-K Filing, Waives Cross-Default

Wait For Valeant's (VRX) 10K - RBC

RBC Capital analyst, Douglas Miehm, noted that Valeant (NYSE: VRX) announced it has agreed to amended terms with its lenders and the terms were generally in line with expectations. However, the analyst remains cautious on the company until the 10K is filed. No change to Sector Perform rating and reducing PT to $65 from $69.

Amendments to term loans will see 100bps increase in interest rate until certain financial metrics are met, 50bps increase thereafter. Following Valeants announcement on March 15th that it would... More

Valeant Pharma (VRX) Short Interest Surges 56% - Guggenheim

In analyzing the latest short interest data for the Specialty Pharmaceutical sector, Guggenheim's Louise Chen notes that Valeant Pharma (NYSE: VRX) short interest rose 56.1% - the largest increase in the sector.

Valeant Pharma short interest was at 18,021,306 shares as of 03/31/2016, versus 11,548,303... More

Valeant Pharma (VRX) Taps Session Low

Valeant Pharma (NYSE: VRX) hit session lows Monday afternoon, falling over 6% from its previous close.

Valeant (VRX) Divestitures 'Unlikely' Near-Term, Says Rodman & Renshaw

Rodman & Renshaw reiterated a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) with an updated price target of $105.00 (prior $118.00). The change reflects higher interest expense.

Analyst Raghuram Selvaraju also said he thinks near-term divestitures are unlikely. Comments follow rumors it would seek a sale of core assets like Bausch + Lomb.

"From our perspective, it is unlikely that Valeant would seek to sell core assets such as the Bausch + Lomb division... More

Valeant Pharma (VRX) Issues Statement on Pearson's Senate Committee on Aging's Subpoena

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) issued the following statement regarding the Senate Committee on Aging's subpoena to depose Valeant Chief Executive Officer, J. Michael Pearson:

"The Board has requested Mr. Pearson's cooperation in connection with a subpoena for deposition from... More

Piper Jaffray Sees Significantly More Downside Risk, Versus Upside Potential to Valeant's (VRX) 2016 Guidance

Piper Jaffray analyst David Amsellem reiterated an Underweight rating on Valeant Pharmaceuticals (NYSE: VRX) after a closer look at 2016 guidance. The firm's conclusion is that there is significantly more downside risk to 2016 guidance than upside potential.

Amsellem commented, "We... More